MedPath

Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis

Completed
Conditions
Neuroendocrine Tumors
Interventions
Other: Metastasized intestinal NET
Registration Number
NCT02646644
Lead Sponsor
University Medical Center Groningen
Brief Summary

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.

Detailed Description

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria
  • age ≥18 years
  • diagnosis of intestinal NET diagnosed by a dedicated NET specialist
  • more than one positive lesion on the 18F-DOPA-PET scan.
  • available CT-scan within 6 months before or after the 18F-DOPA-PET-scan.
Exclusion Criteria
  • no clinical data available at the UMCG, besides the results of the DOPA PET scan.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Metastasized intestinal NETMetastasized intestinal NETWe will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
Primary Outcome Measures
NameTimeMethod
tracer uptake in tumor lesions within patients with intestinal NETat the day of scan

The difference in tracer uptake of tumor lesions within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Secondary Outcome Measures
NameTimeMethod
tracer uptake in tumor lesions within patients with intestinal NET adjusted for uptake of background organat the day of scan

The difference in tracer uptake of tumor lesions adjusted for uptake of background organ within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Trial Locations

Locations (1)

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath